Zacks Research Has Weak Outlook for Omnicell FY2025 Earnings

Omnicell, Inc. (NASDAQ:OMCL) – Analysts at Zacks Research cut their FY2025 earnings per share (EPS) estimates for Omnicell in a note issued to investors on Wednesday, January 7th. Zacks Research analyst Team now expects that the company will post earnings per share of $0.92 for the year, down from their prior forecast of $1.01. Zacks Research currently has a “Hold” rating on the stock. The consensus estimate for Omnicell’s current full-year earnings is $1.09 per share. Zacks Research also issued estimates for Omnicell’s Q4 2025 earnings at $0.25 EPS, Q1 2026 earnings at $0.09 EPS, Q2 2026 earnings at $0.20 EPS, Q3 2026 earnings at $0.29 EPS, Q4 2026 earnings at $0.34 EPS, FY2026 earnings at $0.93 EPS, Q1 2027 earnings at $0.18 EPS, Q2 2027 earnings at $0.27 EPS, Q3 2027 earnings at $0.27 EPS, Q4 2027 earnings at $0.28 EPS and FY2027 earnings at $1.00 EPS.

A number of other research firms have also weighed in on OMCL. Wells Fargo & Company raised their target price on shares of Omnicell from $43.00 to $52.00 and gave the company an “overweight” rating in a report on Monday, January 5th. KeyCorp upgraded shares of Omnicell from a “sector weight” rating to an “overweight” rating and set a $60.00 price objective for the company in a research report on Wednesday, January 7th. Benchmark boosted their target price on shares of Omnicell from $45.00 to $50.00 and gave the stock a “buy” rating in a report on Tuesday, December 9th. Finally, Weiss Ratings restated a “sell (d+)” rating on shares of Omnicell in a research report on Wednesday, October 8th. Four equities research analysts have rated the stock with a Buy rating, three have assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, the stock currently has a consensus rating of “Hold” and a consensus price target of $47.83.

Omnicell Stock Performance

NASDAQ:OMCL opened at $51.39 on Monday. The company has a market cap of $2.31 billion, a price-to-earnings ratio of 119.51, a PEG ratio of 5.45 and a beta of 0.77. Omnicell has a 1 year low of $22.66 and a 1 year high of $55.00. The stock’s 50 day simple moving average is $41.76 and its two-hundred day simple moving average is $34.63. The company has a debt-to-equity ratio of 0.14, a current ratio of 1.44 and a quick ratio of 1.21.

Institutional Investors Weigh In On Omnicell

Several hedge funds have recently modified their holdings of the business. WINTON GROUP Ltd purchased a new position in Omnicell during the 2nd quarter worth $2,692,000. State of Alaska Department of Revenue grew its stake in shares of Omnicell by 8.7% during the second quarter. State of Alaska Department of Revenue now owns 27,906 shares of the company’s stock worth $819,000 after acquiring an additional 2,242 shares during the last quarter. Sumitomo Mitsui Trust Group Inc. increased its holdings in shares of Omnicell by 1.3% during the second quarter. Sumitomo Mitsui Trust Group Inc. now owns 1,423,604 shares of the company’s stock valued at $41,854,000 after acquiring an additional 17,680 shares in the last quarter. Advantage Alpha Capital Partners LP purchased a new position in shares of Omnicell in the 2nd quarter valued at approximately $2,476,000. Finally, Nordea Investment Management AB grew its holdings in shares of Omnicell by 2.1% during the second quarter. Nordea Investment Management AB now owns 125,969 shares of the company’s stock valued at $3,739,000 after buying an additional 2,580 shares during the last quarter. Hedge funds and other institutional investors own 97.70% of the company’s stock.

Insider Buying and Selling at Omnicell

In other news, EVP Corey J. Manley sold 6,106 shares of the stock in a transaction on Thursday, January 8th. The stock was sold at an average price of $49.90, for a total transaction of $304,689.40. Following the transaction, the executive vice president owned 91,674 shares of the company’s stock, valued at approximately $4,574,532.60. This represents a 6.24% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Corporate insiders own 2.52% of the company’s stock.

Key Headlines Impacting Omnicell

Here are the key news stories impacting Omnicell this week:

• Positive Sentiment: Upgrade to Zacks Rank #2 (Buy) — Zacks raised Omnicell to a Buy, signaling growing optimism about its earnings outlook that can support further upside. All You Need to Know About Omnicell (OMCL) Rating Upgrade to Buy
• Positive Sentiment: Analyst upward revisions and favorable coverage — Recent analyst moves (KeyCorp upgrade to overweight, Wells Fargo and Benchmark raising price targets) add conviction for investors and likely helped lift the stock. MarketBeat OMCL coverage overview
• Neutral Sentiment: Upcoming earnings date set for Feb. 5, 2026 — Omnicell will report Q4 and full-year 2025 results then; earnings details and guidance will be the next major catalyst. Investors may trade around guidance and EPS beats/misses. Omnicell to Release Fourth Quarter and Full Year 2025 Financial Results on February 5, 2026
• Neutral Sentiment: Valuation comparison piece — Coverage comparing OMCL to peers (HIMS) offers context for value-oriented investors but is unlikely to move the stock on its own. OMCL vs. HIMS: Which Stock Is the Better Value Option?
• Negative Sentiment: Zacks cut FY2025 EPS estimates — Zacks reduced its FY2025 EPS estimate and lowered its rating previously, which is a drag on sentiment and a reason for caution ahead of results. FY2025 EPS Estimates for Omnicell Reduced by Zacks Research
• Negative Sentiment: Insider sale by EVP — Omnicell EVP Corey Manley sold 6,106 shares (~$304.7k at the time), reducing his holdings ~6.2%; insider selling can be perceived negatively even though the exec retains a large stake. Insider Selling: Omnicell (NASDAQ:OMCL) EVP Sells 6,106 Shares of Stock
• Neutral Sentiment: Short interest note is effectively unchanged/insubstantial — reported short-interest data showed no material short position (odd/possibly stale data), so it’s not a current driver of share moves.

Omnicell Company Profile

Omnicell, Inc is a healthcare technology company that specializes in medication management solutions for hospitals, clinics and pharmacies. The company’s offerings encompass automated dispensing cabinets, pharmacy automation systems, IV compounding devices, and software platforms designed to optimize medication usage, streamline workflow and improve patient safety. Omnicell’s analytics and inventory management tools provide real-time visibility into medication utilization, helping healthcare providers reduce waste, manage controlled substances and ensure regulatory compliance.

Founded in Mountain View, California in 1992, Omnicell has grown through both internal innovation and strategic acquisitions to broaden its portfolio across the medication management continuum.